Orthobiologics is the branch of medicine that focuses on using biological substances and materials to promote the healing and regeneration of musculoskeletal tissues. It includes many treatments, like stem cell therapy, bone grafts, platelet-rich plasma (PRP), and viscosupplementation.
Orthobiologics are commonly used in orthopedic surgeries and procedures to improve recovery, reduce pain, and enhance functional outcomes in conditions like osteoarthritis, tendon injuries, & spinal disorders.
These products can be derived from natural sources like bone, cartilage, or blood, or produced through biotechnological methods. They are designed to enhance the body’s natural healing mechanisms by stimulating tissue growth, reducing inflammation, and improving overall bone
health.
Orthobiologics Market is experiencing exponential expansion as advances in regenerative medicine and biologics gain ground. Rising demand for non-invasive therapies like stem cell therapy, PRP therapy and bone marrow aspirate has contributed to this rapid expansion; such therapies are particularly popular when treating injuries of the musculoskeletal system or degenerative conditions.
Recent advances in orthobiologics focus on improving treatment outcomes, including innovations in biologic products for joint repair and cartilage regeneration. Companies are investing heavily in research to increase both efficacy and safety profiles of these therapies and give patients better alternatives than traditional surgical options.
Orthobiologic products have also become more mainstream in sports medicine, with professional athletes seeking faster recovery times and enhanced results from orthobiologic therapies. As this market gains recognition for their use in treating various orthopedic conditions, demand will likely grow alongside more healthcare providers adopting these therapies into practice.
Opportunities in the Orthobiologics Market are rapidly expanding, particularly in emerging economies with growing access to advanced medical treatments. Partnerships between biotechnology firms and medical device manufacturers have proven fruitful in accelerating product development; and the growing presence of outpatient surgical centers and specialty clinics further adds momentum to global healthcare landscape.
The US Orthobiologics Market
The
US Orthobiologics Market is projected to reach
USD 3.0 billion by the end of 2024 and grow substantially to an expected
USD 4.8 billion market by 2033 at an anticipated
CAGR of 5.4 percent.
The US Orthobiologics Market is expected to hold the largest share of 88.1% in the North American region in 2024. The US orthobiologics market is primarily driven by an aging population increasingly susceptible to musculoskeletal disorders.
Growing adoption of regenerative medicine techniques, such as platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) are some of the key trends in this region. They are focused on technological advancement and research leads to a steady stream of enhanced orthobiologic products.
Key Takeaways
- Market Growth: The global orthobiologics market is projected to grow by b with a CAGR of 5.7%.
- Market Definition: Orthobiologics are biological substances used in orthopedic treatments to promote faster healing of injuries to bones, muscles, ligaments, and tendons.
- Product Analysis: Supply Chain Management is expected to account for the largest revenue share of 45.2%, by 2024.
- Application Analysis: Highway is likely to lead the market with the highest revenue share of 51.5% based on application by 2024.
- End User Analysis: Hospitals are predicted to dominate the market in terms of end users, accounting for the largest revenue of 60.3% by 2024.
- Regional Analysis: North America is expected to lead the global orthobiologics market with a market share of 47.6% by 2024.
Use Cases
- Bone Fracture Repair: Orthobiologics are commonly used to enhance the healing process of bone fractures. Products such as bone grafts, bone morphogenetic proteins (BMPs), and platelet-rich plasma (PRP) are applied to promote faster and more effective bone regeneration, particularly in complex fractures or non-unions.
- Spinal Surgery: In spinal surgeries, orthobiologics can be utilized to facilitate fusion between vertebrae. Bone graft substitutes or autografts are often employed to stimulate bone growth, providing stability and reducing the risk of complications associated with spinal fusion.
- Joint Reconstruction: Orthobiologics play a critical role in joint reconstruction procedures, such as total knee or hip arthroplasty. The use of injectable PRP or stem cells can improve healing, reduce inflammation, and enhance recovery time, ultimately leading to better functional outcomes for patients.
- Tendon and Ligament Repair: In the treatment of tendon and ligament injuries, orthobiologics are used to accelerate healing and improve the quality of tissue repair. For instance, PRP injections can be administered to enhance the healing process in conditions like rotator cuff tears or anterior cruciate ligament (ACL) injuries.
Market Dynamic
Drivers
Increase in Cases of Spinal DisordersThe rise in the cases of musculoskeletal diseases & conditions like osteoarthritis, degenerative disc disease, and bone fractures has been a major driver of the orthobiologics market. An aging population & increased sports injuries further accelerate these conditions, leading to a growing demand for effective treatment options. Orthobiologics, uses natural biological substances to help restore musculoskeletal tissues. It offers minimally invasive treatments that promote faster recovery which makes them a favorable option for patients with these disorders.
High Demand for Viscosupplements
Viscosupplements are hyaluronic acid-based injections that are used to treat osteoarthritis and are in high demand. It is becoming a preferred non-surgical treatment as osteoarthritis continues to be a prevalent condition, particularly in the elderly population. The growing focus on maintaining mobility and quality of life among aging populations has further propelled the demand for viscosupplements, supporting the overall orthobiologics market growth.
Restraints
Patient Preference for Non-Invasive Procedures
The increasing preference among patients for non-invasive treatment options is expected to hinder the growth of the orthobiologics market. As more individuals seek minimally invasive procedures, the demand for traditional orthobiologics may decline.
Rising Costs of Orthobiologics Treatments
The anticipated rise in prices for orthobiologics treatments is projected to impede market growth during the forecast period. Factors such as intricate synthesis processes, stringent manufacturing regulations, and elevated production costs contribute to the high expenses associated with orthobiologics products and therapies.
Opportunities
Increasing Cases of Road Accidents
The growing number of road accidents globally presents a significant opportunity for the orthobiologics market. As road traffic incidents continue to rise, there is an increasing prevalence of orthopedic injuries such as fractures, ligament tears, and joint dislocations. These injuries often require surgical interventions and subsequent rehabilitation, creating a demand for orthobiologic products that can aid in healing and recovery.
Obesity as a Contributor to Orthopedic Disorders
Obesity is a significant contributor to various orthopedic disorders, leading to a growing opportunity for the orthobiologics market. Excess body weight places increased stress on joints, particularly the knees, hips, and spine, leading to conditions such as osteoarthritis, joint pain, and mobility issues. As the prevalence of obesity rises globally, so does the incidence of related orthopedic problems. This creates a heightened demand for effective treatment options that can alleviate pain and restore function.
Trends
Advanced Imaging Techniques
Fluoroscopy and ultrasound imaging techniques have significantly accelerated the adoption of minimally invasive surgery (MIS) in orthopedics. Surgeons use these tools to more precisely visualize anatomical structures during procedures for improved precision & outcomes. It reduces the complications resulting in faster healing times post-surgery while orthobiologics play an essential part in healing and rehabilitation post-procedure.
Minimally Invasive Surgical Instruments
The introduction of advanced minimally invasive surgical instruments, including arthroscopic tools and robotic-assisted systems, has revolutionized orthopedic procedures. These innovations enable surgeons to perform complex surgeries through smaller incisions, resulting in reduced tissue damage, shorter hospital stays, and quicker recoveries. As patients increasingly prefer less invasive options, the demand for orthobiologics that support healing and tissue regeneration after MIS continues to grow, fueling market expansion in this area.
Research Scope and Analysis
By Product
Visco supplementation is expected to lead the orthobiologics market with a revenue share of 45.2% by 2024, as this treatment involves injecting hyaluronic acid directly into joints (typically the knee) to ease pain and increase mobility among those suffering from osteoarthritis. Synovial fluid provides cushions and lubricates joints naturally found within our bodies; mimicking this natural function has proven an increasingly popular treatment choice worldwide, especially as millions are affected by osteoarthritis; driving its global prevalence significantly higher and increasing market opportunities for treatment options like this one.
The demand for non-invasive solutions like visco supplementation continues to increase with osteoarthritis cases on the rise among older populations. Its broad adoption can be attributed to its ease of use, minimal side effects, & high patient acceptance. Hence, this treatment has been prescribed when dealing with mild to moderate osteoarthritis which is partly responsible for its dominant market status.
Generally, the second leading product in orthobiologics market is stem cell therapy which has rapidly evolved since it is capable of repairing damaged tissues as well as reducing inflammation. This revolutionary therapy involves the use of MSCs obtained from body parts such as bone marrow or adipose tissue to restore broken components of the joint and other body structures related to illnesses like osteoarthritis or tendinopathy.
Some of the trends that have helped shape the conditions necessary for the growth of stem cell therapy are; increased global health care expenditure and niche areas such as biomolecular individualism which point to precision medicines. In addition, consequent innovations result from increased progress in biotechnology and regenerative medicine technologies.
By Application
Spinal Fusion is projected to dominate the orthobiologics market with a 51.5 % market share by 2024 due to the global increase in spinal disorders. Spinal fusion surgery aims at stabilizing and relieving pain by joining two or more vertebrae together into one solid bone, to restrict movement and avoid further injury to the spine. Due to increasing cases of spine-related conditions like herniated discs, scoliosis and spinal stenosis, demand for spinal fusion procedures has seen dramatic surge.
Orthobiologics such as bone grafts, bone morphogenetic proteins (BMPs), and demineralized bone matrices (DBMs), are frequently utilized during spinal fusion surgeries to enhance healing processes and ensure successful outcomes. Due to their ability to provide strong bone stability and promote rapid healing, bone morphogenetic proteins, demineralized bone matrixes, autografts, and allografts have become staples in these surgeries and play an instrumental role in propelling their expansion.
Innovations in surgical techniques and an increase in minimally invasive spinal fusion procedures have further solidified this application segment's dominance of the orthobiologics market. Reconstructive surgery has also experienced considerable demand due to an aging global population that is more vulnerable to spinal degenerative conditions and rising rates of musculoskeletal disorders.
Reconstructive surgeries should continue experiencing notable growth over the coming years as more individuals opt for reconstructive treatments as part of aging population-induced spinal degeneration and increased demand.
By End User
Hospitals are expected to hold the highest revenue share by end-users in orthobilogics market by the end of 2024 with a 60.3% revenue share. Since orthobiologics are employed carefully in healthcare facilities with appropriate
medical infrastructure, hospitals remain at the frontline of orthobiologics application.
Orthobiologics gives you a minimally invasive treatment which optimizes your body’s own healing just in case you didn’t know that would reduce the overall need for extensive surgeries or even longer hospital stays. Hospitals also install imaging and surgical technologies, which assist orthopedic surgeons to apply orthobiologics properly in directing the growth of tissues as well as quick healing.
These organizations also attend to a huge patient population, many of which present with chronic orthopedic disorders, managed through orthobiologic procedures like bone grafts, stem cell therapy, and viscosupplements. They have a leadership role in clinical research trials and use of newer Orthobiologic products AdventHealth. Orthopedic clinics represent another prominent segment, providing outpatient musculoskeletal treatment such as viscosupplementation or minor joint surgeries which contributed significantly to their significant market presence.
The Global Orthobiologics Market Report is segmented based on the following
By Product
- Visco-supplementation
- Stem Cell Therapy
- Demineralized Bone Matrix (DBM)
- Allograft
- Bone Morphogenetic Protein (BMP)
- Synthetic Bone Substitutes
By Application
- Spinal Fusion
- Reconstructive Surgery
- Osteoarthritis and Degenerative Arthritis
- Trauma Repair
- Maxillofacial and Dental Applications
By End User
- Hospitals
- Orthopedic Clinics
- Ambulatory Care Centers
- Research and Academic Institutes
- Dental Clinics and Facilities
Regional Analysis
North America is projected to lead the global orthobiologics market
with 47.6% market share by revenue in 2024 due to its highly developed healthcare infrastructure, rising prevalence of orthopedic conditions, and its dedication towards research and development for regenerative medicine.
The region is widely known for the prevalence of conditions like osteoarthritis, degenerative disc disease, and sports-related injuries - all of which create demand for orthobiologic products such as viscosupplementation therapy, stem cell therapies, or bone graft replacement alternatives.
Due to an expanding aging population in both countries, demand for treatments to enhance mobility and decrease joint pain has skyrocketed. Thanks to advanced healthcare systems in these two nations, accessing innovative ortho-biologic products such as BIONOS may now be easier. Hospitals & clinics across this region are known for their advanced technologies, which offers global adoption of novel therapies.
In addition, North America boasts many leading medical device and biotechnology firms which foster an innovative culture. Companies heavily invested in research & clinical trials are furthering the advancement of orthobiologic treatments, leading to faster growth of the market. Furthermore, higher healthcare spending and robust insurance coverage allow more patients access to expensive therapies like stem cell therapy or spinal fusion surgery.
By Region
North America
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Competitive Landscape
Key players in the orthobiologics market are employing innovative strategies for business growth, including expanding product portfolios, forming partnerships and collaborations, engaging in mergers and acquisitions, and broadening their market footprint.
The market is marked by substantial M&A activity among top companies, driven by the need to meet the increasing demand for demineralized bone matrix (DBM). Vendors are strengthening their market position through strategies such as strategic alliances, collaborations, geographic expansion, M&As, regulatory approvals, and the launch of new products or services.
In recent years, the orthobiologics sector has played a pivotal role in advancing regenerative medicine. Major players like Integra LifeSciences, Medtronic Plc, and Stryker Corporation are driving market demand through significant investment in research and development. To thrive in an increasingly competitive market, companies must offer affordable products.
Some of the prominent players in the global orthobiologics market are
- Medtronic Plc
- DePuy Synthes
- Zimmer Biomet
- Stryker Corporation
- Bioventus LLC
- Anika Therapeutics, Inc.
- Orthofix, Inc.
- Globus Medical
- Arthrex, Inc.
- Bone Biologics Corp.
- Other Key Players
Recent Development
- In November 2023, OssDsign AB announced a strategic pivot to focus solely on the U.S. orthobiologics market, positioning itself as a pure-play orthobiologics company. The company's main focus will be on OssDsign Catalyst, a nanosynthetic bone graft product with over 90% gross margins, designed to stimulate healthy bone growth in spinal fusion surgeries and is easily scalable.
- In October 2023, Orthofix Medical Inc. launched OsteoCove, a bioactive synthetic graft that received 510(k) clearance for use in various orthopedic and spinal procedures.
- In September 2023, NuVasive, Inc. merged with Globus Medical, Inc. to enhance their offering of musculoskeletal procedural solutions and technologies for both surgeons and patients.
- In June 2023, Anika Therapeutics, Inc. secured an additional 510(k) clearance from the U.S. FDA for its Tactoset Injectable Bone Substitute.
- In March 2023, LifeNet Health introduced ViviGen MIS to the U.S. market, the first viable bone matrix to provide lineage-committed bone cells, specifically for use in minimally invasive spine surgeries.
- In February 2022, Orthofix Medical Inc. launched Opus BA, a synthetic bone graft designed for lumbar and cervical spine fusions, available in strip and putty forms to fill bone gaps and voids in the skeletal system.
Report Details
| Report Characteristics |
| Market Size (2024) |
UUSD 1,085.5 Bn |
| Forecast Value (2033) |
USD 1,637.8 Bn |
| CAGR (2024-2033) |
4.7% |
| Historical Data |
2018 – 2023 |
| The US Market Size (2024) |
USD 256.5 Bn |
| Forecast Data |
2025 – 2033 |
| Base Year |
2023 |
| Estimate Year |
2024 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
| Segments Covered |
By Type (Supply Chain Management, Distribution Management, Material Management, Shipment Packaging, and Channel Management), By Transportation (Highway Transportation, Air Transportation, Sea Transportation, Railway Transportation), By End User (E-commerce, Automotive, Consumer packaged goods, Aerospace, and government, Food & beverages, and Others) |
| Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
| Prominent Players |
United Parcel Service of America, Inc., Exel Logistics, XPO Logistics, Inc., A.P. Møller - Mærsk A/S, DHL International GmbH, Kuehne + Nagel International AG, Tibbett and Britten, FedEx Corporation, Deutsche Bahn AG, Nippon Express Co., Ltd., DSV A/S, SNCF Group, and Other Key Players |
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users) and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively. |